Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization


Bristol Myers Squibb (NYSE: BMY) today announced that on December 6, 2023, its Board of Directors authorized the repurchase of an additional $3 billion of the company's common stock under the company's multi-year share repurchase program.

With this increase, the company's total outstanding share repurchase authorization is approximately $5 billion. The program enables management to execute repurchases at its discretion.

The timing and amount of any share repurchases under the authorization will be determined at a future date by management at its discretion and based on market conditions and other considerations. Share repurchases under the authorizations may be made through a variety of methods, which may include open market purchases, pursuant to pre-set trading plans meeting the requirements of Rules 10b5-1 and 10b-18 under the Securities Exchange Act of 1934, in privately negotiated transactions, block trades, accelerated share repurchase transactions, or any combination of such methods. The program does not obligate Bristol Myers Squibb to acquire any particular amount of its common stock, and the repurchase program may be suspended or discontinued at any time at the company's discretion.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the execution of share repurchase transactions. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporatefinancial-news


These press releases may also interest you

at 01:35
Regulatory News: MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune...

at 01:29
DBN Group, a leading high-tech agricultural enterprise, has opened its Phoenix International Innovation Park for global applications from high-quality agricultural biotech companies. This initiative seeks to establish an open innovation and...

at 00:01
Graduates who went to medical school for three years performed equally well on tests of skill and knowledge as their peers who followed a four-year program, a new study shows....

14 oct 2024
Aidoc, a global pioneer in clinical AI solutions, today announced the expansion of its partnership with Integral Diagnostics (IDX), the leading provider of AI-driven medical imaging services, across Australia and New Zealand. This enhanced...

14 oct 2024
PharmAbcine, Inc. (KOSDAQ: 208340), a clinical-stage public company developing next-generation therapeutics to address unmet medical needs, today...

14 oct 2024
At the World Health Summit in Berlin today (15 October), the Pasteur Network (PN) announced the launch of a pioneering project to empower local researchers, governments and communities in low- and middle-income countries to tackle the health impacts...



News published on and distributed by: